Drug Discovery Outsourcing 2014 2024

Drug Discovery Outsourcing World
Market Forecast 2014-2024 & Future
Prospects for Leading Companies

©notice
This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of visiongain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each purchase and single copy is for personal use only.

Contents
1. Executive Summary
1.1 Market Highlights
1.2 Overview of the Report Content
1.3 Research and Analysis Methods
1.4 Glossary of Terms Related to Drug Discovery Outsourcing

2. An introduction to Drug Discovery Outsourcing
2.1 What is Outsourcing?
2.1.1 Drug Discovery Outsourcing: Forming Global Networks
2.2 Why Outsource Drug Discovery?
2.2.1 The Move from Tactical to Strategic Outsourcing
2.2.2 The Advantages of Drug Discovery Outsourcing
2.2.3 Technological Advances Making In-House Drug Development Unsustainable
2.2.4 Emerging Markets Offering Reprieve from the Effects of Cost Pressures and Declining
R&D Budgets
2.2.5 Strategic Partnerships: A Prequel to CRO Acquisition
2.2.6 Outsourcing to Improve Efficiency and Reduce Time-to-Market
2.3 Typically Outsourced Processes in Drug Discovery
2.4 A Paradigm Shift for Drug Development
2.4.1 Collaboration with Academia is Key for Pipeline Replenishment
2.5 Quality of Service is Integral for CRO Growth
2.6 Outsourcing: Reducing the Cost of Innovation

3. Global Drug Discovery Outsourcing Market 2014-2024
3.1 Drug Discovery Outsourcing: Global Market Overview
3.1.1 The Global Drug Discovery Outsourcing Market in 2012 and 2013

www.visiongain.com

Contents
3.2 Global Drug Discovery Outsourcing: Market Forecast 2014-2024
3.2.1 Changing Market Shares by Sector 2014-2024
3.3 Global Chemistry Services Outsourcing Market 2014-2024
3.3.1 The Global Chemistry Services Outsourcing Market in 2012 and 2013
3.3.1.1 Libraries: Important for Cost Reduction and Time Efficiency
3.3.1.2 Custom Synthesis: A Major Driver for Long-Term Strategic Partnerships
3.3.1.3 Building Blocks: Promotes Efficiency of Drug Synthesis
3.3.2 Global Chemistry Services Outsourcing Forecast 2014-2024
3.4 Global Biology Services Outsourcing Market 2014-2024
3.4.1 The Global Biology Services Outsourcing Market in 2012 and 2013
3.4.1.1 Target Identification
3.4.1.2 Target Validation
3.4.2 Global Biology Services Outsourcing Forecast 2014-2024
3.5 Global Lead Optimization Market 2014-2024
3.5.1 The Global Lead Optimization Market in 2012 and 2013
3.5.1.1 ADMET Screening: To Prevent Late Stage Failure of Clinical Trials
3.5.2 Global Lead Optimisation Forecast 2014-2024
3.6 Global Lead Identification and Screening Outsourcing Market 2014-2024
3.6.1 The Global Lead Identification and Screening Outsourcing Market in 2012 and 2013
3.6.1.1 Methodologies of Lead Identification
3.6.2 Global Lead Identification and Screening Outsourcing Market: Forecast 2014-2024

4. Leading National Markets 2014-2024
4.1 Drug Discover Outsourcing – A Game of Supply versus Demand
4.1.1 The Global Distribution of Drug Discovery Outsourcing in 2012 and 2013
4.2 Leading National Markets: Forecast 2014-2024
4.2.1 Changing Market Shares by Region 2014-2024
4.3 Regional Drug Discovery Outsourcing Markets: Analysis and Forecasts 2014-2024
4.3.1 United States: Patent Expiries Boosting Pipeline Investment

www.visiongain.com

Contents
4.3.2 The EU5 Markets
4.3.2.1 EU5: Changing Market Shares by Country 2014-2024
4.3.2.2 Germany: Europe’s Largest Drug Discovery Outsourcing Market
4.3.2.3 UK: A Service-Oriented Market
4.3.2.4 France: Market Dominated by Large CROs
4.3.2.5 Italy: Heavy Investment from Multinational CROs will Drive Growth
4.3.2.6 Spain: An Immature Market with Potential
4.3.3 Japan: An Aging Population Putting a Strain on Pharma
4.3.4 The BRIC Nations: Rapid Growth will Fuel the Global Market
4.3.4.1 China: Rapid Market Expansion Fuelled by Acquisitions
4.3.4.2 India: R&D Infrastructure Needed for Market Boom
4.3.4.3 Brazil: The Largest Pharma Market in Latin America
4.3.4.4 Russia: A Highly Fragmented Market
4.3.5 South Korea: A Pharmaceutical Powerhouse of the Future

5. Leading Companies Offering Drug Discovery Services
5.1 Drug Discovery Outsourcing: An Expanding Marketplace
5.2 What Makes a Successful Contract Research Organisation?
5.2.1 A Business Model that Encourages Cost Reduction
5.2.2 A Workforce with Proven Expertise
5.2.3 Good Working Relationship: A Requisite for Outsourcing
5.2.4 Adequate Intellectual Property Protection
5.2.5 Huge Emphasis is placed on Communication and Timeliness
5.3 Leading Companies in the Drug Discovery Outsourcing Arena
5.4 Albany Molecular Research (AMRI)
5.4.1 SMARTSOURCING for Enhanced Decision-Making
5.4.2 AMRI’s Drug Discovery Services
5.4.3 AMRI’s Licensing Agreements and Drug Discovery Collaborations
5.4.4 AMRI Revenue Forecast 2014-2024

www.visiongain.com

Contents
5.5 Aptuit
5.5.1 INDIGO: Aptuit’s Accelerated Drug Development Programme
5.5.2 Strategic Partnerships Strengthening Aptuit’s Outlook
5.6 Charles River Laboratories
5.6.1 Charles River: Strong Sales of Research Models Boosts Revenue
5.6.2 Charles Rivers: Corporate Restructuring to Maximise Efficiency
5.6.3 Charles River: Revenue Analysis and Forecast 2014-2024
5.7 Covance
5.7.1 Refocusing Early-Stage Efforts
5.7.2 Covance Strategic Partnerships
5.7.3 Covance: Revenue Analysis and Forecast 2014-2024
5.8 Cyprotex: An ADME-Tox Service Provider
5.8.1 Cyprotex: Revenue Analysis and Forecast 2014-2024
5.9 Domainex: Pipeline Products Showing Promise
5.10 Evotec: Discovery Alliances and Development Partnerships
5.10.1 Action Plan 2016 – Leadership in Drug Discovery Solutions
5.10.2 Evotec: Revenue Analysis and Forecast 2014-2024
5.11 Galapagos
5.11.1 Galapagos – Recent Activity
5.12 GenScript: A Biology-Focused Research Company
5.12.1 GenScript: Agreements and Partnerships
5.13 Pharmaceutical Product Development (PPD): A Leading CRO
5.13.1 PPD: Agreements, Strategic Partnerships and Private Merger
5.13.2 PPD’s Expansion in the Asian Markets
5.13.3 PPD and BioDuro: A Key Acquisition for Chinese Market Dominance
5.14 Quintiles: The World’s Largest Biopharmaceutical Services Company
5.14.1 Quintiles: Acquisition of Advion Bioanalytical Labs
5.14.2 Quintiles – New Developments
5.14.3 Quintiles: Revenue Analysis and Forecast 2014-2024
5.15 WIL Research Laboratories
5.16 WuXi AppTec: China’s Leading CRO

www.visiongain.com

Contents
5.16.1 WuXi AppTec: Revenue Analysis, 2008-2012
5.16.2 WuXi’s Strategic Partnerships and Recent Developments
5.16.3 WuXi AppTec: Revenue Forecast 2014-2024

6. Drug Discovery Outsourcing Market: Analysis and Trends
6.1 SWOT Analysis of the Drug Discovery Outsourcing Market 2014-2024
6.2 Strengths
6.2.1 Cost Reduction: A Central Driver for Outsourcing
6.2.2 Efficient Turnaround Times is Key for the Growth of Outsourcing
6.2.3 Acquisitions and Mergers allows for a more Comprehensive Service Provision
6.3 Weaknesses
6.3.1 The Negative Effects of Falling R&D Spending
6.3.2 Market Saturation and Poorly-Defined Service Offerings
6.4 Opportunities
6.4.1 The Available Scope for the Expansion of CROs
6.4.2 Targeted Therapies: Advances in Biologics and Orphan Drugs
6.4.3 Orphan Drug Development: An Opportunity for Higher Premiums
6.4.4 The Rise of Biologics and Biosimilars
6.4.5 The Multi-directional Expansion of CROs
6.4.6 The Rise of Virtual Pharma Companies
6.5 Threats
6.5.1 A Competitive Market Causing Smaller CROs to Miss Out
6.5.2 Private-Public Alliances May Become a Threat to Drug Discovery Outsourcing
6.5.3 Intellectual Property Leaks and the Challenges of Technology Transfer
6.5.4 Resource Sharing by Pharma Companies Could Restrain CRO Growth
6.6 Porter’s Five Force Analysis of the Drug Discovery Outsourcing Market
6.6.1 Power of Suppliers: Medium
6.6.2 Threat of Substitutes: Medium
6.6.3 Rivalry among Competitors: High

www.visiongain.com

Contents
6.6.4 Bargaining Power of Buyers: High
6.6.5 Threat of New Entrants: Medium

7. Expert Opinions
7.1 Interview with Dr Barbara Slusher, Professor of Neurology, Psychiatry, and Neuroscience at
Johns Hopkins University and co-Founder and President, Academic Drug Discovery Consortium
7.1.1 Current State of the Drug Discovery Outsourcing Industry
7.1.2 Drug Discovery Collaborations between Pharma and Academia
7.1.3 Academic Research: A Restraint to CRO Growth?
7.1.4 The Changing Outsourcing Model: Implications for Pharma R&D
7.1.5 The Move towards Shared Risk Partnerships
7.1.6 Hot Therapeutic Areas in Drug Discovery
7.1.7 Views on the Future Prospects of the Market
7.2 Interview with Dr Mark Craighead, Director of Scientific Strategy, Redx Pharma
7.2.1 Changes in the Industry’s Pricing Model
7.2.2 Redx Pharma’s Services and Growth Plans
7.2.3 Is Outsourcing Earlier the Key to Solving Pharma’s R&D Problems?
7.2.4 Appealing Therapeutic Areas and the Role of the Asian Markets

8. Conclusion
8.1 Market Overview
8.2 A Move towards Biology Services
8.3 The Rise of the Asian Outsourcing Industry
8.4 Unmet Therapeutic needs will Stimulate Drug Discovery Drive
8.5 Alliances and Collaborations Will Continue to Dominate the Market

www.visiongain.com

Contents
List of Tables
Table 2.1 Indication of Functions Outsourced in the Different Stages of the Drug R&D Process, 2013
Table 2.2 Selected Drug Discovery Outsourcing Alliances 2012- 2013
Table 2.3 Selected Drug Discovery Outsourcing Alliances 2009- 2012
Table 3.1 PhRMA’s Historical Estimate for its Member’s R&D Spending ($bn)
Table 3.2 The Global Drug Discovery Outsourcing Market: Revenues ($bn), Market Shares (%) and
Growth (%) by Sector, 2012 and 2013
Table 3.3 The Global Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%,
CAGR%) by Sector, 2012-2017
Table 3.4 The Global Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%)
by Sector, 2017-2024
Table 3.5 Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Sector, 2012-2017,
2017-2024, and 2012-2024
Table 3.6 The Global Drug Discovery Outsourcing Market: Revenue ($bn) by Sector, 2012, 2017,
2024
Table 3.7 The Global Drug Discovery Outsourcing Market: Market Share (%) by Sector, 2012, 2017,
2024
Table 3.8 The Chemistry Services Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%),
2012-2024
Table 3.9 The Biology Services Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%),
2012-2024
Table 3.10 The Global Lead Optimisation Outsourcing Market: Revenue Forecast ($bn, AGR%,
CAGR%), 2012-2024
Table 3.11 Selected Drug Discovery Lead Optimisation Partnerships
Table 3.12 Selected Methods for Sourcing Lead Compounds, 2013
Table 3.13 The Global Lead Identification and Screening Market: Revenue Forecast ($bn, AGR%,
CAGR%), 2012-2024
Table 4.1 The Global Drug Discovery Outsourcing Market: Revenues ($bn) and Growth (%) by
Region, 2012 and 2013

www.visiongain.com

Contents
by Region, 2012-2017
by Region, 2017-2024
Table 4.4 Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Region, 2012-2017,
2017-2024, and 2012-2024
Table 4.5 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Region, 2012,
2017, 2024
Table 4.6 The US Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank, Market
Share (%) and CAGR (%), 2012-2024
Table 4.7 US Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%, CAGR%), 20122024
Table 4.8 The EU5 Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Market Share
(%) and CAGR (%), 2012-2024
Table 4.9 The EU5 Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%, CAGR%) by
Country, 2012-2017
Table 4.10 The EU5 Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%, CAGR%)
by Country, 2017-2024
Table 4.11 The EU5 Drug Discovery Outsourcing Market Forecast: CAGR (%) by Country, 20122017, 2017-2024, and 2012-2024
Table 4.12 The EU5 Drug Discovery Outsourcing Market: Market Shares (%) by Country, 2012,
2017, 2024
Table 4.13 The German Drug Discovery Outsourcing Market Forecast: Market Size ($m), Rank,
Market Share (%) and CAGR (%), 2012-2024
Table 4.14 The German Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%,
CAGR%), 2012-2024
Table 4.15 The UK Drug Discovery Outsourcing Market Forecast: Market Size ($m), Rank, Market
Share (%) and CAGR (%), 2012-2024
Table 4.16 The UK Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%, CAGR%),
2012-2024
Table 4.17 The French Drug Discovery Outsourcing Market Forecast: Market Size ($m), Rank,

www.visiongain.com

Contents
Table 4.18 The French Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%,
CAGR%), 2012-2024
Table 4.19 The Italian Drug Discovery Outsourcing Market Forecast: Market Size ($m), Rank,
Table 4.20 The Italian Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%,
CAGR%), 2012-2024
Table 4.21 The Spanish Drug Discovery Outsourcing Market Forecast: Market Size ($m), Rank,
Table 4.22 The Spanish Drug Discovery Outsourcing Market: Revenue Forecast ($m, AGR%,
CAGR%), 2012-2024
Table 4.23 The Japanese Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank,
Table 4.24 The Japanese Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%,
CAGR%), 2012-2024
Table 4.25 The Chinese Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank,
Table 4.26 The Chinese Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%,
CAGR%), 2012-2024
Table 4.27 The Indian Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank,
Table 4.28 The Indian Population: Demographic Forecast by Age Group (%), 2015, 2020, 2025
Table 4.29 The Indian Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%,
CAGR%), 2012-2024
Table 4.30 The Brazilian Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank,
Table 4.31 The Brazilian Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%,
CAGR%), 2012-2024
Table 4.32 The Russian Drug Discovery Outsourcing Market Forecast: Market Size ($bn), Rank,
Table 4.33 The Russian Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%,
CAGR%), 2012-2024

www.visiongain.com

Contents
Table 4.34 The South Korean Drug Discovery Outsourcing Market Forecast: Market Size ($bn),
Rank, Market Share (%) and CAGR (%), 2012-2024
Table 4.35 The South Korean Drug Discovery Outsourcing Market: Revenue Forecast ($bn, AGR%,
CAGR%), 2012-2024
Table 5.1 Albany Molecular Research (AMRI): Historical Revenue ($m, AGR %), 2008-2012
Table 5.2 AMRI: Services offered and Descriptions, 2013
Table 5.3 AMRI: Drug Discovery and Development Programmes and Project Stage
Table 5.4 Albany Molecular Research (AMRI): DDS Revenue Forecast ($m, AGR %, CAGR%), 20122024
Table 5.5 Aptuit: Services Offered and their Descriptions, 2013
Table 5.6 Charles River Laboratories: Selected Services Provided, 2013
Table 5.7 Charles River: Historical Revenue ($m, AGR %), 2010-2012
Table 5.8 Charles River: Historical Revenue ($m) by Segment, 2009-2012
Table 5.9 Charles River: Revenue Forecast ($m, AGR %, CAGR%), 2012-2024
Table 5.10 Covance: Historical Revenue ($bn) by Business Segment, 2009-2012
Table 5.11 Covance: Early Development Revenue Forecast ($m, AGR %, CAGR%), 2012-2024
Table 5.12 Selected Cyprotex Partnerships, 2013
Table 5.13 Cyprotex: Historical Revenue ($m) by Region, 2010-2012
Table 5.14 Cyprotex: Revenue Forecast ($m, AGR %, CAGR%), 2012-2024
Table 5.15 Domainex’s Collaborations and Partnerships, 2013
Table 5.16 Evotec: Historical Revenue ($m, AGR %), 2008-2012
Table 5.17 Evotec Action Plan 2016: Leadership in Drug Discovery Solutions
Table 5.18 Evotec: Revenue Forecast ($m, AGR %, CAGR%), 2012-2024
Table 5.19 Galapagos Pipeline Projects and Development stages, 2013
Table 5.20 Galapagos: Historical operating Income ($m) by Business Sector, 2011 and 2012
Table 5.21 Genscript: Services Offered and Descriptions, 2013
Table 5.22 Quintiles: Historical Revenue ($bn, AGR %), 2008-2012
Table 5.23 Quintiles: Revenue Forecast ($bn, AGR %, CAGR%), 2012-2024
Table 5.24 WuXi AppTec: Pharmaceutical Laboratory Services and Descriptions, 2013
Table 5.25 WuXi AppTec: Historical Revenue ($m) by Business Segment, 2008-2012
Table 5.26 WuXi AppTec: Laboratory Services Revenue Forecast ($m, AGR %, CAGR%), 2012-2024

www.visiongain.com

Contents
Table 6.1 Drug Discovery Outsourcing: Market Drivers, 2014-2024
Table 6.2 Drug Discovery Outsourcing: Market Restraints, 2014-2024
Table 6.3 SWOT Analysis of the Drug Discovery Outsourcing Industry, 2014-2024
Table 6.4 NIH Biomarker Definitions, 2013
Table 8.1 Projected Global Drug Discovery Outsourcing Market Size ($bn, CAGR%): 2012, 2017,
2020, 2024
Table 8.2 The Global Drug Discovery Outsourcing Market: Revenue ($bn) by Sector, 2012, 2017,
2020, 2024
Table 8.3 The Global Drug Discovery Outsourcing Market: Market Share (%) by Sector, 2012, 2017,
2020, 2024

www.visiongain.com

Contents
List of Figures
Figure 2.1 Selected Tasks being Outsourced in the Pharma Industry, 2013
Figure 2.2 Typical Stages of the Drug Development Cycle
Figure 3.1 PhRMA’s Historical Estimate for its Member’s R&D Spending ($bn)
Figure 3.2 The Global Drug Discovery Outsourcing Market: Revenues ($bn) by Sector, 2012 and
2013
Figure 3.3 The Global Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2017
Figure 3.4 The Global Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2017-2024
Figure 3.5 Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Sector, 2012-2017
Figure 3.8 The Global Drug Discovery Outsourcing Market: Revenue ($bn) by Sector, 2012, 2017,
2024
Figure 3.9 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Sector, 2012
Figure 3.12 The Chemistry Services Outsourcing Market: Revenue Forecast ($bn), 2012-2024
Figure 3.13 The Biology Services Outsourcing Market: Revenue Forecast ($bn), 2012-2024
Figure 3.14 An Overview of ADMET Screening in Drug Discovery
Figure 3.15 The Global Lead Optimisation Outsourcing Market: Revenue Forecast ($bn), 2012-2024
Figure 3.16 Typical Steps in the Lead Screening Process
Figure 3.17 The Global Lead Identification and Screening Market: Revenue Forecast ($bn), 20122024
Figure 4.1 The Global Drug Discovery Outsourcing Market: Revenues ($bn) by Region, 2012
Figure 4.2 US, EU5, and Japan Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 20122024
Figure 4.3 China, India, South Korea, Brazil, and Russia Drug Discovery Outsourcing Market:
Revenue Forecast ($bn), 2012-2024
Figure 4.4 Global Drug Discovery Outsourcing Market Forecast: CAGR (%) by Region, 2012-2017

www.visiongain.com

Contents
Figure 4.7 The Global Drug Discovery Outsourcing Market: Market Shares (%) by Region, 2012
Figure 4.10 US Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024
Figure 4.11 Germany, UK, France, Italy, and Spain Drug Discovery Outsourcing Market: Revenue
Forecast ($m), 2012-2024
Figure 4.12 The EU5 Drug Discovery Outsourcing Market Forecast: CAGR (%) by Region, 20122024
Figure 4.13 The EU5 Drug Discovery Outsourcing Market: Market Shares (%) by Country, 2012
Figure 4.14 The German Drug Discovery Outsourcing Market: Revenue Forecast ($m), 2012-2024
Figure 4.15 The UK Drug Discovery Outsourcing Market: Revenue Forecast ($m), 2012-2024
Figure 4.16 The French Drug Discovery Outsourcing Market: Revenue Forecast ($m), 2012-2024
Figure 4.17 The Italian Drug Discovery Outsourcing Market: Revenue Forecast ($m), 2012-2024
Figure 4.18 The Spanish Drug Discovery Outsourcing Market: Revenue Forecast ($m), 2012-2024
Figure 4.19 Japanese Over-65 Population and Forecast (%): 2010, 2013, 2035, 2060
Figure 4.20 The Japanese Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024
Figure 4.21 Chinese Demographics: Over 65 Population and Forecast (millions), 1950, 2010, 2050
Figure 4.22 The Chinese Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024
Figure 4.23 The Indian Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024
Figure 4.24 The Brazilian Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024
Figure 4.25 The Russian Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 2012-2024
Figure 4.26 The South Korean Drug Discovery Outsourcing Market: Revenue Forecast ($bn), 20122024
Figure 5.1 Albany Molecular Research (AMRI): Historical Revenue ($m), 2008-2012
Figure 5.2 Albany Molecular Research (AMRI): Revenue Forecast ($m), 2012-2024
Figure 5.3 Charles River: Historical Revenue ($m), 2010-2012
Figure 5.4 Charles River: Historical Revenue ($m) by Segment, 2012
Figure 5.5 Charles River: Revenue Forecast ($m), 2012-2024
Figure 5.6 Covance: Historic Revenue ($bn), 2009-2012
Figure 5.7 Covance: Revenue ($bn) by Segment, 2012

www.visiongain.com

Contents
Figure 5.8 Covance: Early Development Revenue Forecast ($m), 2012-2024
Figure 5.9 Cyprotex: Historical Revenue ($m), 2010-2012
Figure 5.10 Cyprotex: Revenue Shares (%) by Region, 2012
Figure 5.11 Cyprotex: Revenue Forecast ($m), 2012-2024
Figure 5.12 Evotec: Historical Revenue ($m), 2008-2012
Figure 5.13 Evotec: Revenue Forecast ($m), 2012-2024
Figure 5.14 Galapagos: Revenue Share (%) by Business Sector, 2012
Figure 5.15 Quintiles: Historical Revenue ($bn), 2008-2012
Figure 5.16 Quintiles: Revenue Forecast ($bn), 2012-2024
Figure 5.17 WuXi AppTec: Historical Revenue ($m) by Business Segment, 2008-2012
Figure 5.18 WuXi AppTec: Laboratory Services Revenue Forecast ($m), 2012-2024
Figure 6.1 Porter’s Five Force Analysis of the Drug Discovery Outsourcing Market, 2013
Figure 8.1 Projected Global Drug Discovery Outsourcing Market Size ($bn): 2012, 2017, 2020, 2024
Figure 8.2 The Global Drug Discovery Outsourcing Market: Revenue ($bn) by Sector, 2012, 2017,
2020, 2024
Figure 8.3 Global Over-60 Population Forecast (%): 1950, 2009, 2050
Figure 8.4 The Global Drug Discovery Outsourcing Market: Market Share (%) by Sector, 2012,
2017, 2020, 2024

www.visiongain.com

Contents
Companies Mentioned in this Report
Abbott
Accugenix
Advion Bioanalytical
Albany Molecular Research Inc (AMRI)
Andromeda Biotech (Teva)
Apredica (Cyprotex)
Aptuit
Argenta (Galapagos)
AstraZeneca
Bayer
Behrman Capital
BioCity
BioDuro (PPD)
BioFocus (Galapagos)
Biopontis Alliance
Boehringer Ingelheim
Bristol-Myers Squibb
Caprion Proteomics
Carlyle Group
Catalent Pharma Solutions
Cerebricon (Charles River)
Charles River Laboratories
ChemBridge
ChemDiv
Compound Focus (Evotec)
Covance
Crucell
Cyprotex

www.visiongain.com

Contents
Discovery Partners International
Domainex
Dow AgroSciences
Dow Chemical Company
Elan
Eli Lilly
Evotec
Fidelity Growth Partners India (FGPI)
Fidelta (Galapagos)
Furiex Pharmaceuticals
Galapagos
Genentech
GenScript
GlaxoSmithKline (GSK)
Glycoform
Great Lakes Chemical Corporation
Hangzhou Tigermed Consulting
Hellman & Friedman
Hypha Discovery
i3 Research (inVentiv Health)
ICON
Inpharmatica
InSphero
InVentiv Health
Johnson & Johnson (J&J)
Janssen Pharmaceutical Group
Kinaxo
Knopp Biosciences
ICON
Immatics
JOINN Laboratories

www.visiongain.com

Contents
Laurus Labs
Lonza
MAB Discovery
MedImmune
Merck & Co.
Microsoft
Midwest BioResearch (WIL Research)
Millipore
Novartis
Ono Pharmaceutical
Oxford Asymmetry International
Parexel
Peking Union Lawke Biomedical Development Limited (PUL)
Pfizer
Myriad RBM
Pharmaceutical Product Development (PPD)
Pharmidex
PharmaNet Development Group (inVentiv Health)
Pharminox
Piedmont Research Center (Charles River)
PRA International
ProSkelia
ProStrakan
Proteome Sciences
Proteros Biostructures GmbH (Proteros)
ProtonMedia
Quintiles
Ricerca Biosciences (WIL Research)
Roche
Samsung
Sanofi

www.visiongain.com

Contents
Sareum Holdings Plc
Servier
ShangPharma Corporation
Shionogi
Sirius Analytical
Solvo Biotechnology
Swiss Pharma Contract
Sygnature Discovery
SYNthesis Med Chem
Taijitu Biologics
Takeda
Teva
The Dow Chemical Company
Tibotec
TRAC Microbiology
TransGenic
UCB
VitualScopics
WIL Research Laboratories
WuXi AppTec
WuXi PharmaTech

www.visiongain.com

Contents
Organisations Mentioned in this Report
American Cancer Society
Associação Brasileira de CROs (Abracro)
Beijing Genomics Institute
Bundesverband Medizinischer Auftragsinstitute (BVMA)
CHDI Foundation
Dundee University
Food and Drug Administration (US FDA)
Indiana Clinical and Translational Sciences Institute (CTSI)
Johns Hopkins University
Massachusetts General Hospital
National Institute for Population and Social Security Research (IPSS)
National Institutes of Health (NIH)
Pharmaceutical Research and Manufacturers of America (PhRMA)
Russian Corporation of Nanotechnologies
Southwestern Medical Center
The European Innovative Medicine Initiative (IMI)
The European CRO Federation (EUCROF)
The Institute of Cancer Research
The Organization for Economic Cooperation and Development (OECD)
University of Manchester
University of North Carolina
Wellcome Trust
World Health Information Science Consultants (WHISCON)
World Health Organization (WHO)
World Trade Organization (WTO)

www.visiongain.com

Drug Discovery Outsourcing: World Market Forecast
2014-2024 & Future Prospects for Leading Companies
Figure 2.1 Selected Tasks being Outsourced in the Pharma Industry, 2013

Animal
models

Clinical trial
data
manageme
t

Pre-Clinical
and Clinical
Trials

Registratio
n and
Marketing

Clinical trial
manageme
nt

Manufacturin
g and
packaging

Regulator
y affairs

Lifecycle
manageme
nt

Target
identification

Assay
developme
nt and
ADMET

Drug
Discovery
and
Developme
nt

High
throughput
screening

Drug
manufacture

Sales and
marketing

Lead
Optimisation

Source: Visiongain 2013

2.2 Why Outsource Drug Discovery?
The global recession of 2008, triggered by the US housing bubble, has added to the global
pharmaceutical industry’s existing challenges of declining pipeline products. The industry is
currently experiencing one of the most challenging periods in its history, in terms of the level of
capital available to be used. The cost of taking a drug to the market has risen rapidly over the past
three decades. Development costs for a drug is now estimated to be anywhere between $800m
and $1bn. The pharmaceutical industry has invested a large amount of money into R&D over the
past few decades but the number of novel drug entities reaching the clinic has declined. All of

www.visiongain.com

Page 26

Table 4.35 The South Korean Drug Discovery Outsourcing Market: Revenue Forecast
($bn, AGR%, CAGR%), 2012-2024

2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
South Korean Market
($bn)
Annual Growth (%)
CAGR (% 2012-2017 &
2017-2024)
CAGR (% 2012-2024)

0.2

0.2 0.2 0.3 0.3 0.4 0.5 0.6 0.6 0.7 0.8 0.9 1.0
18 20 22 22 21 18 15 15 14 13 14 12
20.6

14.4
16.9


Figure 4.26 The South Korean Drug Discovery Outsourcing Market: Revenue Forecast
($bn), 2012-2024
1.2

1.0
0.9

1.0

Revenue ($bn)

0.8
0.7

0.8
0.6
0.6
0.4
0.2

0.2

0.2

0.3

0.3

0.4

0.5

0.6

0.0
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Year


Visiongain believes that the tax breaks afforded to local drug makers that invest in research and
development, in particular, the subsidies afforded to those involved in joint drug-development

www.visiongain.com

Page 110

Table 5.3 AMRI: Drug Discovery and Development Programmes and Project Stage
Disease Area/Target
Antibacterials
GLY-T
5-HT6
MCH-1
Biogenic Amines
5-HT3
Tubulin Inhibitor

Lead
Pre-clinical
Optimisation Development

Lead Discovery

Phase I
Clinical

Phase II
Clinical

Infection
Schizophrenia
Cognition
Obesity
Central Nervous System
Irritable Bowel Syndrome
Oncology

Source: AMRI 2013, Visiongain 2013

5.4.4 AMRI Revenue Forecast 2014-2024
Visiongain predicts sustained growth for AMRI’s future revenue. Increasing demand for chemistry
services, especially from the US market will help AMRI grow contract revenue from its DDS
business segment (Discovery, Drug development and Small scale manufacturing). This will reach
$123.6m in 2017 (Figure 5.2). This represents a CAGR of 11.0% from 2012 to 2017 (Table 5.4).

Table 5.4 Albany Molecular Research (AMRI): DDS Revenue Forecast ($m, AGR %,
CAGR%), 2012-2024
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
AMRI's DDS Revenue
($m)
Annual Growth Rate (%)
CAGR (% 2012-2017 &
2017-2024)
CAGR (% 2012-2024)

73.5 83.7 94.6 106.0 114.5 123.6 131.0 138.9 148.6 156.1 162.3 168.8 173.9
14

13

12

8

8
11.0

6

6

7

5

4

4

3
5.0
7.4


www.visiongain.com

Page 118

Drug Discovery Outsourcing 2014 2024

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Kürzlich hochgeladen

Kürzlich hochgeladen (20)

Empfohlen

Empfohlen (20)

Drug Discovery Outsourcing 2014 2024